R21/Matrix-M malaria vaccine shows promising results

A recent study found that the R21/Matrix-M malaria vaccine could prevent approximately 200,000 cases and 650 deaths per 100,000 children in areas with seasonal malaria, and 180,000 cases and 630 deaths in regions with year-round transmission. The vaccine, recommended by the WHO, is developed by Oxford University and manufactured by Serum Institute of India. India aims to eliminate malaria by 2030 and has significantly reduced cases and deaths. However, the vaccine needs trials in an Indian setting.